Background: Aims and objectives were to evaluate the impact of high-flow nasal cannula (HFNC) therapy on ABG parameters, oxygenation indices, and clinical outcomes in children with moderate to severe respiratory distress admitted to the PICU. Methods: This prospective observational study was conducted over 10 months at a tertiary care center. A total of 133 children aged 1 month to 14 years with respiratory distress were included. Severity was assessed using the Pediatric respiratory severity score (PRESS). Clinical and laboratory parameters were recorded at baseline, 1 hour, 12 hours, and 24 hours after initiation of HFNC therapy. Oxygenation indices, including A-a gradient, respiratory index, P/F ratio, S/F ratio, ROX index, and modified ROX index, were analyzed. Statistical analysis was performed using SPSS version 25.0. Results: Of the 133 children, 90.23% had severe respiratory distress. Significant improvements were observed in heart rate, respiratory rate, and SpO₂ over time (p<0.05). ABG analysis showed significant reductions in pCO₂ and lactate, along with improvements in pO₂, HCO₃, and base excess (p<0.05). Both ABG-dependent and independent oxygenation indices improved significantly within 24 hours (p<0.0001). HFNC failure and need for mechanical ventilation were low (1.5% each). Median ICU and hospital stay were 4 and 6 days, respectively, with 100% survival. Conclusions: HFNC therapy is a safe and effective non-invasive respiratory support modality in children with moderate to severe respiratory distress. It significantly improves oxygenation, ABG parameters, and clinical outcomes, while reducing the need for invasive ventilation.
No takes yet. Share an insight, caveat, or question.
Lokeswari et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: